Peptide Antibiotics Market Size, Share & Trends Analysis Report By Product Type, By Disease, By Route Of Administration (Oral, Injectable, Topical), By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global peptide antibiotics market size was valued at USD 4.37 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 4.6% from 2022 to 2030. The factors responsible for driving the growth of the market are increasing demand of peptide antibiotics in hospitals and clinics, increasing prevalence of diseases such as, bacterial skin infections, blood stream infections, and hospital acquired infections. Moreover, rising product approvals and product launches are also expected to propel the growth forward during the forecast period.

The market for peptide antibiotics is expected to witness growth opportunities owing to rising incidence of central line associated blood stream infections. According to the Australian Institute of Health and Welfare, during 2019-2020, 700 Australian public hospitals reported 1,428 cases of Staphylococcus aureus blood stream infections. Amongst them, most of the infections were methicillin sensitive Staphylococcus aureus infections. All types of blood stream infections are serious infections and can cause prolonged hospital stays. Thus, the surge in prevalence of blood stream infections is likely to support market growth during the forecast period.

The rising incidence of antimicrobial resistance is also expected to provide lucrative growth opportunities for the peptide antibiotics market. For instance, according to CDC’s report on Antibiotics Resistance Threats in US 2019 report, 2.8 million antimicrobial resistance cases are recorded in the United States every year with about 35,000 deaths every year. Moreover, CDC is implementing funding activities through CDC’s Antimicrobial Resistance Initiative that support over 50 state health departments, and various local health departments. CDC has also collaborated with state and local health departments, federal agencies, and private sector to mitigate antimicrobial resistance threat.

Furthermore, from year 2016 to 2020 CDC has invested in over 330 novel antibiotic resistance projects across 30 countries to combat antimicrobial resistance. Ongoing product approvals and strategic initiatives undertaken by key players such as, partnerships, collaborations, product launches, expansions are expected to cater market growth during the forecast period. For instance, in September 2021 AuroMedics Pharma LLC announced that it has received an approval from USFDA to manufacture Daptomycin for an injection.

Moreover, in July 2022, Boehringer Ingelheim, Evotec SE, and bioMérieux announced that they have created a joint venture for making next generation of antimicrobials for fight against antimicrobial resistance. Furthermore, the availability of robust product portfolio of peptide antibiotics is also anticipated to positively impact the growth of the market for peptide antibiotics during the forecast period. For instance, Bacitracin vial manufactured by Xellia Pharmaceuticals is indicated for the treatment of infants with pneumonia and empyema. Bacitracin is the examples of poly peptide product.

Product Type Insights

The non-ribosomal synthesized peptide antibiotics segment held the largest revenue share of 72.2% in 2021 and is likely to maintain its dominance over the forecast period. The growth of the non-ribosomal synthesized peptide antibiotics is attributed by increasing demand for non-ribosomal synthesized antibiotics and rising availability of non-ribosomal synthesized antibiotics.

There are several non-ribosomal synthesized antibiotics available in market for peptide antibiotics. For instance, BLEOMYCIN (Glyco peptide product) manufactured by Pfizer Inc., is a non-ribosomal synthesized peptide antibiotic isolated from a strain of Streptomyces verticillus. BLEOMYCIN is used in the treatment of squamous cell carcinoma, testicular carcinoma, and lymphoma. Moreover, Bacitracin vial manufactured by Xellia Pharmaceuticals is indicated for the treatment of infants with pneumonia and empyema.

Disease Insights

The skin infection segment held the largest revenue share of 30.3% in 2021 and is likely to dominate the market during the forecast period. The growth of the skin infection segment is augmented by rising prevalence of skin infections such as, cellulitis, impetigo, furuncles, carcuncles, and others, and wide availability of products for treatment of bacterial skin infections. For instance, CUBICIN RF (daptomycin for injection) a type of lipo peptide product manufactured by Merck & Co., Inc. is used for the treatment of pediatric patients and adults with complicated skin and skin structure infections caused by S. aureus, S.pyrogenes, S. agalactiae.

However, the blood stream infection segment is anticipated to register fastest growth rate during the forecast period. The growth of the segment is augmented by rising incidences of blood stream infections, rising awareness about blood stream infections, and availability of robust product portfolio for management of blood stream infections. For instance, Polymyxin B vials manufactured by Xellia PHARMACEUTICALS is used for the treatment of blood-stream infections due to strains such as, E-Coli, Pseudomonas aeruginosa, H. influenza.

Distribution Channel Insights

The hospital pharmacies segment held the highest revenue share of 45.4% in 2021, whereas the retail pharmacies segment is expected to register fastest growth rate during the forecast period. Rising prescriptions of peptide antibiotics owing to various kind of bacterial skin infections, ophthalmic infections is a major factor expected to drive the retail pharmacy segment growth. However, the growth of hospital pharmacy segment is augmented by rising prevalence of blood stream infection, hospital acquired infection, and prolonged hospital stays.

Route Of Administration Insights

The injectable route of administration segment held the largest revenue share of 42.7% in 2021 and is expected to maintain its dominance during the forecast period. The growth of the injectable segment is attributed to factors such as availability of large number of peptide antibiotics in injectable form, efficiency, and better bioavailability from injectable peptide antibiotics.

There are a large number of products available in injectable form. For instance, DALVANCE manufactured by AbbVie Inc is administered by intravenous route as an infusion. DALVANCE is used for the treatment of various kind of skin infections. Moreover, vancomycin hydrochloride manufactured by Pfizer, Inc is given by IV infusion for the treatment of severe infections caused by susceptible strains of methicillin-resistant staphylococci.

Regional Insights

North America dominated the market for peptide antibiotics and accounted for revenue share of 40.9% in 2021 followed by Europe. Factors such as presence of large number of market players and strategic initiatives taken by key players are some of the major factors responsible for the growth.

Moreover, rising demand for antibiotics in this region, and increase in R&D activities in the region are also expected to drive the industry during the forecast period. Asia Pacific is expected to be the fastest growing region over the forecast period owing to factors such as increase in prevalence of various infectious diseases, rising geriatric population, and surge in awareness amongst patients about their health.

Key Companies & Market Share Insights

The market is highly competitive due to the presence of large number of key players worldwide. Moreover, various organic as well as inorganic developments undertaken by key players are anticipated to fuel industry growth over the forecast period. For instance, in July 2022, Boehringer Ingelheim, Evotec SE, and bioMérieux announced that they have created a joint venture for making next generation of antimicrobials for fight against antimicrobial resistance. Some of the prominent players in the peptide antibiotics market include:

• Pfizer Inc.

• Merck & Co., Inc.

• AbbVie Inc

• GSK Group of Companies

• Sandoz International GmbH

• Xellia Pharmaceuticals

• AuroMedics Pharma LLC

• Theravance Biopharma 

Peptide Antibiotics Market Report Scope

Global Peptide Antibiotics Market Segmentation 

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global peptide antibiotics market report on the basis of product type, disease, route of administration, distribution channel, and region:

• Product Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Ribosomal Synthesized Peptide Antibiotics

  • Non-Ribosomal Synthesized Peptide Antibiotics

• Disease Outlook (Revenue, USD Million, 2018 - 2030)

  • Skin Infection

  • HABP/VABP

  • Blood Stream Infection

  • Others

• Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

  • Oral

  • Injectable

  • Topical

  • Others

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • Saudi Arabia

    • South Africa

    • UAE